Saturday 17 October 2026
Export PTHS’s income statement to Excel — free account
Pelthos Therapeutics Inc.
PTHS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 23.1%, free cash flow fell 1,615.0% and total debt rose 2,692.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
20.15
0.11
−0.54%
Follow PTHS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 0.00 | 2.31 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.62) | (9.32) | (5.30) | (13.05) | |
P/B ratio |
1.47 | 1.50 | 3.61 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.00 | 0.00 | 0.00 | 3.41 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.34) | (3.28) | (3.00) | (3.49) | |
EV/FCF |
(4.34) | (3.28) | (2.97) | (3.47) | |
Quick Ratio |
0.90 | 1.03 | 1.76 | 1.22 | |
Current Ratio |
2.01 | 2.05 | 2.79 | 1.98 | |
Net Debt/EBITDA |
1.00 | (1.24) | (2.94) | (2.89) | |
Debt/Assets |
0.00% | 24.11% | 45.04% | 50.90% | |
Debt/Equity |
0.00 | 0.81 | 3.40 | (46.58) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.63 | |
Operating CF/Net income |
0.94 | 0.29 | 0.52 | 0.33 | |
Capex/Depreciation |
0.00 | (0.08) | (0.11) | 0.00 | |
Interest Coverage |
(11.41) | (9.13) | (5.56) | (7.25) | |
Research and Development Expense of Revenue |
1.96% | 3.98% | 1.71% | 3.85% | |
Selling, General and Administrative Expense of Revenue |
265.03% | 196.71% | 193.51% | 177.36% | |
Intangible Assets out of Total Assets |
0.50 | 0.49 | 0.43 | 0.45 | |
Share Based Compensation of Revenue |
37.31% | 19.16% | 17.49% | 17.69% | |
Graham Net Nets |
(0.21) | (0.65) | (0.81) | (0.75) | |
Graham Number |
0.00 | 0.00 | 0.00 | 16.55 | |
Earnings Yield |
(61.00%) | (74.55%) | (130.80%) | (101.63%) | |
Free Cash Flow Yield |
(19.84%) | (38.75%) | (50.84%) | (42.58%) | |
Revenue per Share |
2.42 | 4.99 | 3.29 | 4.41 | |
Operating CF per Share |
(4.98) | (3.32) | (3.96) | (2.17) | |
Capex per Share |
0.00 | (0.05) | (0.06) | 0.00 | |
Free Cash Flow per Share |
(4.98) | (3.38) | (4.02) | (2.17) | |
Cash per Share |
4.66 | 9.58 | 9.73 | 6.94 | |
Shareholders Equity per Share |
19.03 | 20.68 | 5.82 | (0.42) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
19.03 | 20.68 | 5.82 | (0.42) | |
Free Cash Flow |
(15.26) | (6.35) | (13.32) | (7.67) | |
Working Capital |
24.99 | 27.42 | 44.80 | 31.40 | |
Capital Expenditures |
— | (0.10) | (0.19) | 0.00 | |
Net Current Asset Value |
(18.42) | (38.11) | (56.31) | (75.50) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.02 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.47 | 2.44 | 4.38 | 5.42 | |
Average Assets |
64.29 | 65.88 | 73.14 | 69.09 | |
Average Common Equity |
28.41 | 18.08 | 7.54 | (4.00) |
Columns are period end dates